Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2808 participants.
Also called NCT05262803
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,808 participants
- Sponsor
- Rikke Sorensen
- Registry
-
NCT05262803
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Recruiting
Technical summary
Registry record NCT05262803. Randomized; single masking; primary purpose treatment. Start 2022-06-17 (actual); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction
- Acronym
- Dan-DAPT
- Condition
- Myocardial Infarction
- Intervention (Genetic)
- CYP2C19*2/*3
- Intervention (Other)
- Shorter DAPT duration
- Lead sponsor
- Rikke Sorensen
Record details
- Record id
cardio:ct-nct05262803- Content hash
840537a0ce0335f8a765955ae353f0dd17d573a7d824c237c23462740e6a6234